PRMT1 is required for the generation of MHC-associated microglia and remyelination in the central nervous system

Jeesan Lee1, Oscar David Villarreal1, Yu Chang Wang2

  • 1Segal Cancer Center, Lady Davis Institute for Medical Research and Gerald Bronfman Department of Oncology and Departments of Biochemistry, Human Genetics, and Medicine, McGill University, Montreal, Canada.

Life Science Alliance
|June 15, 2022
PubMed

Insights

Protein arginine methyltransferase 1 (PRMT1) is essential for microglia regeneration, promoting central nervous system remyelination in a multiple sclerosis mouse model. Its absence impairs repair and prolongs inflammation.

Area of Science:

  • Neuroscience
  • Immunology
  • Molecular Biology

Background:

  • Multiple sclerosis (MS) involves failed remyelination, leading to neurodegeneration.
  • Microglia, innate immune cells, can promote remyelination but their regenerative regulators are unclear.

Purpose of the Study:

  • To identify regulators of regenerative microglia activation in the central nervous system (CNS).
  • To investigate the role of PRMT1 in microglia-mediated remyelination.

Main Methods:

  • Used a cuprizone-diet induced de- and remyelination mouse model.
  • Employed single-cell RNA sequencing to analyze microglial populations.
  • Investigated PRMT1's effect on histone modifications (H3K27ac) and gene expression.

Main Results:

  • PRMT1 deficiency in microglia impaired remyelination, reduced oligodendrocyte progenitor cells, and prolonged inflammation.
  • PRMT1 loss hindered the formation of a specific MHC-associated microglia cluster.
  • PRMT1-deficient microglia showed reduced H3K27ac peaks and suppressed MHC- and IFN-associated gene expression.

Conclusions:

  • PRMT1 is a critical regulator of MHC- and IFN-associated microglia.
  • PRMT1 is necessary for effective CNS remyelination in the context of demyelinating disease.

Related Concept Videos